Compare ASIC & CRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASIC | CRON |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 890.2M | 1.0B |
| IPO Year | 2025 | N/A |
| Metric | ASIC | CRON |
|---|---|---|
| Price | $18.77 | $2.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $25.25 | N/A |
| AVG Volume (30 Days) | 84.7K | ★ 1.5M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 504.00 | N/A |
| EPS | ★ 0.17 | 0.09 |
| Revenue | ★ $405,657,000.00 | $132,357,000.00 |
| Revenue This Year | $14.72 | $17.63 |
| Revenue Next Year | $44.71 | $30.76 |
| P/E Ratio | $107.54 | ★ $27.99 |
| Revenue Growth | ★ 68.10 | 19.00 |
| 52 Week Low | $16.35 | $1.60 |
| 52 Week High | $25.30 | $3.43 |
| Indicator | ASIC | CRON |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 47.95 |
| Support Level | $17.49 | $2.54 |
| Resistance Level | $19.18 | $2.63 |
| Average True Range (ATR) | 0.73 | 0.10 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 74.29 | 47.67 |
Ategrity Specialty Insurance Co Holdings Formerly Ategrity Specialty Holdings LLC is a specialty insurance company dedicated to providing excess and surplus products to small to medium-sized businesses across the United States. It offers property and casualty insurance solutions tailored to meet the needs of SMBs. The company focuses on are Real Estate, Hospitality, Construction, and Retail.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.